



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Uldrick, TS, A Mosam, F Shaik, G Friedland, D Skadden, JP Jordaan, J Aboobaker, and HM Coovadia. 2009. "Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770." <i>Infectious Agents and Cancer</i> 4 (Suppl 2): P41. doi:10.1186/1750-9378-4-S2-P41. http://dx.doi.org/10.1186/1750-9378-4-S2-P41 .
Published Version	doi:10.1186/1750-9378-4-S2-P41
Accessed	February 17, 2015 8:33:40 AM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581179
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

Poster presentation

Open Access

Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770

TS Uldrick*^{1,2}, A Mosam^{3,4}, F Shaik^{2,4}, G Friedland⁷, D Skadden⁸, JP Jordaan⁵, J Aboobaker⁴ and HM Coovadia⁶

Address: ¹Mailman School of Public Health, Columbia University, New York, New York, USA, ²Columbia University – South Africa Fogarty AIDS International Training and Research Program, New York, New York, USA, ³PI NCT00380770, ⁴Department of Dermatology, Doris Duke Medical Research Institute; Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa, ⁵Department of Oncology, Doris Duke Medical Research Institute; Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa, ⁶Victor Daitz Chair of HIV Research, Doris Duke Medical Research Institute; Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa, ⁷Yale University, New Haven, Connecticut, USA and ⁸Harvard Medical School, Boston, Massachusetts, USA

* Corresponding author

from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Bethesda, MD, USA. 6–7 October 2008

Published: 17 June 2009

Infectious Agents and Cancer 2009, **4**(Suppl 2):P41 doi:10.1186/1750-9378-4-S2-P41

This abstract is available from: <http://www.infectagentscancer.com/content/4/S2/P41>

© 2009 Uldrick et al; licensee BioMed Central Ltd.

Objective

AIDS-associated Kaposi's Sarcoma (KS) is an increasing public health problem in KwaZulu-Natal, South Africa. The optimal management of AIDS-associated KS in sub-Saharan Africa is unknown. NCT00380770 is a single center randomized clinical trial of 112 patients with AIDS-associated KS who received a nivirapine based anti-viral regimen (ARV) alone, or with chemotherapy (doxorubicin, bleomycin and vincristine) between 2003 and 2007. We evaluated 1-year overall survival (OS) and the ACTG staging system in our study population.

Design

Cohort study.

Methods

Baseline TIS staging information is available for all patients. One-year survival data is available for 105 study subjects, with only seven subjects lost to follow-up. OS was evaluated using Kaplan-Meier hazard function methodology. Survival functions were generated for subjects with 0, 1, 2 and 3 adverse prognostic variables using the

modified ACTG TIS staging system (CD4 cut-off = 150). Univariate and multivariate Cox proportional hazard regression was performed to evaluate the prognostic value of individual and combined variables on OS in the study

Table 1: Baseline demographics

Randomization	ARV 53%	Combination 47%
Sex	F 55%	M = 45%
Age Range	18–62	
Region	Urban 70%	Rural 30%
T	0 = 14%	I = 86%
I	0 = 45%	I = 55%
S	0 = 56%	I = 44%




Figure 1
Overall survival.

cohort. Survival analysis was performed with Stata 10 for Macintosh.

Results

Baseline characteristics are listed in Table 1. One-year OS in the overall cohort was 76.6 percent. For subjects with 0, 1, 2 and 3 adverse prognostic risk factors, the one-year OS was 100 percent, 89 percent, 73 percent and 61 percent (Figure 1). Results from univariate and multivariate Cox proportional hazard regression analyses are listed in Table 2. For the Cox proportional hazards regression model including T, I, and S, the LR $\chi^2(3) = 8.45$, with $p = 0.0375$.

Conclusion

In NCT00380770, 1-year OS in a cohort of AIDS-associated KS subjects in a resource limited setting is dramatically improved compared to historical sub-Saharan cohorts prior to the availability of ARVs. The ACTG Staging system is clinically useful in resource-limited settings. It is notable that for 86 percent T = 1 disease and universal ARV use HIV-associated systemic illnesses, which included 15 subjects with tuberculosis, is the most significant prognostic factor. Analysis of response rates, overall

Table 2: Cox Proportional Hazard Regression

Prognostic variable	Univariate		Multivariate	
T	HR = 2	p = 0.34	HR = 1.8	p = 0.44
I	HR = 2	p = 0.11	HR = 1.8	p = 0.16
S	HR = 2.7	p = 0.02	HR = 2.4	p = 0.04

HR = Hazard ratio of death for score of 1 compared to score of 0

survival, adverse events, and quality-of-life between the two arms in NCT00380770 is ongoing.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp